Spirit Small Vessel Registry (SPIRIT SV).
Phase of Trial: Phase III
Latest Information Update: 01 May 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Atherosclerosis; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms SPIRIT SV
- Sponsors Abbott Laboratories
- 10 Jun 2017 Biomarkers information updated
- 31 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 May 2012 Planned End Date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.